OOIR: Observatory of International Research

Papers

(The TQCC of Drug Resistance Updates is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)

Article	Citations
Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance	304
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment	188
Anticancer drug resistance: An update and perspective	169
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming	163
Antimicrobial peptides for combating drug-resistant bacterial infections	163
The role of alternative splicing in cancer: From oncogenesis to drug resistance	149
Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance	128
Hypoxia as a driver of resistance to immunotherapy	119
Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification	118
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies	117
Therapeutic strategies to overcome taxane resistance in cancer	115
Novel nanomedicines to overcome cancer multidrug resistance	115
FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy	110
Overcoming cancer chemotherapy resistance by the induction of ferroptosis	83
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses	81
Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function	76
Current therapy and drug resistance in metastatic castration-resistant prostate cancer	74
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects	74
Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs	73
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade	69
Long non-coding RNA mediated drug resistance in breast cancer	63
Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance	62
ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance	61
Exosomal circular RNAs: A chief culprit in cancer chemotherapy resistance	60
Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers	58

Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine	56
Impact of cancer metabolism on therapy resistance – Clinical implications	55
Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer	53
Loss of cancer-associated fibroblast-derived exosomal DACT3-AS1 promotes malignant transformation and ferroptosis-mediated oxaliplatin resistance in gastric cancer	52
GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer	52
Thirty years of VRE in Germany – “expect the unexpected”: The view from the National Reference Centre for Staphylococci and Enterococci	51
N6-methyladenosine-modified circular RNA QSOX1 promotes colorectal cancer resistance to anti-CTLA-4 therapy through induction of intratumoral regulatory T cells	50
Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition	50
Exosomal LOC85009 inhibits docetaxel resistance in lung adenocarcinoma through regulating ATG5-induced autophagy	50
Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms	49
The key roles of the lysine acetyltransferases KAT6A and KAT6B in physiology and pathology	49
COVID-19 update: The race to therapeutic development	45
Selenium and tellurium in the development of novel small molecules and nanoparticles as cancer multidrug resistance reversal agents	44
Cross-resistance and drug sequence in prostate cancer	44
Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma	40
Cuproptosis: A novel therapeutic target for overcoming cancer drug resistance	39
Resistance-proof antimicrobial drug discovery to combat global antimicrobial resistance threat	37
Emerging role of autophagy in anti-tumor immunity: Implications for the modulation of immunotherapy resistance	37
Molecular Modeling Strategies of Cancer Multidrug Resistance	35
The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies	35
The role of extracellular vesicles in the transfer of drug resistance competences to cancer cells	35
KIAA1429 promotes tumorigenesis and gefitinib resistance in lung adenocarcinoma by activating the JNK/ MAPK pathway in an m6A-dependent manner	35
Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From prediction to druggability	35
In vitro biomimetic models for glioblastoma-a promising tool for drug response studies	34
Nanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment	33
Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mTOR signaling pathway in triple negative breast cancer	33
The strategic roles of four enzymes in the interconnection between metabolism and oncogene activation in non-small cell lung cancer: Therapeutic implications	33
Paclitaxel resistance related to nuclear envelope structural sturdiness	32
Revolutionizing non-conventional wound healing using honey by simultaneously targeting multiple molecular mechanisms	29
Rewiring chaperone-mediated autophagy in cancer by a prion-like chemical inducer of proximity to counteract adaptive immune resistance	29
Antibiotic failure: Beyond antimicrobial resistance	28
Why may citrate sodium significantly increase the effectiveness of transarterial chemoembolization in hepatocellular carcinoma?	28
Precision medicine: Ray of hope in overcoming cancer multidrug resistance	28
Enzymatic bionanocatalysts for combating peri-implant biofilm infections by specific heat-amplified chemodynamic therapy and innate immunomodulation	27